reSET-O

Pear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics

by

Dig­i­tal health firm Pear goes pub­lic, rais­ing $175 mil­lion (phar­mafo­rum):

Pear will make its debut on the exchange today after com­bin­ing with Thim­ble Point – a spe­cial pur­pose acqui­si­tion com­pa­ny (SPAC) – in a deal that side­stepped the con­ven­tion­al ini­tial pub­lic offer­ing (IPO) route and has pro­pelled its val­u­a­tion to around $1.6 bil­lion … Pear spe­cialis­es in pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) based on cog­ni­tive behav­iour­al ther­a­py (CBT) tech­niques that can deliv­ered remote­ly to [patients via a dig­i­tal device. It has three apps approved by the FDA, includ­ing reSET and reSET‑O for peo­ple liv­ing with sub­stance and opi­oid use dis­or­ders, respec­tive­ly, and a tool for chron­ic insom­ni­acs called Som­ryst. [Read more…] about Pear Ther­a­peu­tics rais­es $175M and goes pub­lic via SPAC deal rais­ing the pro­file of pre­scrip­tion dig­i­tal therapeutics

Prescription software firm Pear Therapeutics to go public via $1.6 billion SPAC deal, harnessing 3 FDA-authorized products and 14 candidates

by

Pear Ther­a­peu­tics to Go Pub­lic in Rough­ly $1.6 Bil­lion SPAC Deal (The Wall Street Journal):

Med­ical tech­nol­o­gy com­pa­ny Pear Ther­a­peu­tics Inc. has agreed to go pub­lic by merg­ing with a blank-check com­pa­ny with ties to the Pritzk­er Vlock Fam­i­ly Office, bet­ting on the grow­ing role of pre­scrip­tion dig­i­tal therapeutics.

The pro­posed merg­er would give the com­bined com­pa­ny a pro for­ma equi­ty val­ue of about $1.6 bil­lion. [Read more…] about Pre­scrip­tion soft­ware firm Pear Ther­a­peu­tics to go pub­lic via $1.6 bil­lion SPAC deal, har­ness­ing 3 FDA-autho­rized prod­ucts and 14 candidates

Ohio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments

by

Ohio is third state to fund Pear’s dig­i­tal ther­a­peu­tics to tack­le addic­tion (phar­mafo­rum):

The com­pa­ny has been push­ing for more reim­burse­ment of its three mar­ket­ed DTx prod­ucts in the US fol­low­ing a first FDA approval in 2017.

Pear said that the Ohio Depart­ment of Men­tal Health and Addic­tion Ser­vices (OhioMHAS) and Recov­ery­Ohio are pro­vid­ing access to Pear’s FDA-approved DTx reSET and reSET‑O, for treat­ment of sub­stance use dis­or­der and opi­oid use dis­or­ders, respec­tive­ly. [Read more…] about Ohio joins Indi­ana and Ken­tucky in fund­ing Pear Ther­a­peu­tics’ dig­i­tal addic­tion treatments

Pear Therapeutics raises $80M; finds cost savings of $2,150 per patient with opioid use disorder

by

Pear Ther­a­peu­tics rais­es $80M in push for reim­burse­ment (Med­C­i­ty News):

Pear Ther­a­peu­tics raised $80 mil­lion in fund­ing, which it plans to use as part of a push for cov­er­age of its dig­i­tal ther­a­peu­tics. The Boston-based com­pa­ny has three FDA-cleared prod­ucts, includ­ing dig­i­tal ther­a­peu­tics for sub­stance use dis­or­der, opi­oid use dis­or­der, and most recent­ly, insom­nia. [Read more…] about Pear Ther­a­peu­tics rais­es $80M; finds cost sav­ings of $2,150 per patient with opi­oid use disorder

Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health

by

___

Pear Ther­a­peu­tics rakes in $50M to devel­op addi­tion­al dig­i­tal ther­a­peu­tics (Mobi­Health­News):

“Boston- and San Fran­cis­co-based Pear Ther­a­peu­tics, mak­er of a pre­scrip­tion dig­i­tal ther­a­peu­tic plat­form, announced today the clo­sure of $50 mil­lion in Series B fund­ing. The round was led by Sin­ga­pore-based invest­ment com­pa­ny Temasek, with par­tic­i­pa­tion from return­ing investors 5AM Ven­tures, Arbore­tum Ven­tures, and JAZZ Ven­ture Part­ners, as well as new part­ners Novar­tis, EDBI, and the Bridge Builder’s Col­lab­o­ra­tive [Read more…] about Pear Ther­a­peu­tics rais­es $50M to devel­op and mar­ket a port­fo­lio of dig­i­tal ther­a­peu­tics for men­tal health